Key result
Self-financed rotavirus vaccination demonstrated a vaccine effectiveness of 75.1% (95% CI 65-86%) against rotavirus-positive acute gastroenteritis in children ≤60 months of age.
Why the study?
Does self-financed rotavirus vaccination reduce the incidence and hospitalizations of acute gastroenteritis in children ≤60 months of age?
Observational (n=109,605)
Yes
Does self-financed rotavirus vaccination reduce the incidence and hospitalizations of acute gastroenteritis in children ≤60 months of age?
Effect estimate: VE 75.1% (95% CI 65-86)
Despite low coverage, self-financed rotavirus vaccination significantly reduced the incidence and hospitalizations of RV-positive acute gastroenteritis in young children in Turkey.
Self-financed rotavirus vaccination was associated with lower RV-positive AGE; extends observational evidence but leaves open need for randomized confirmation before policy change.
Rotavirus (RV) vaccines have been available in Turkey since 2006. These vaccines are not funded by the National Health System, so consequently their coverage rate in children has reached only 13–18%. We conducted a retrospective record review including all children ≤60 months of age presenting to study hospitals with suspected or clinical acute gastroenteritis (AGE) between 2012 and 2018. During the study, 109,605 children ≤60 months of age were admitted to pediatric out-patient clinics and pediatric emergency room, of which 15,501 (14%) were diagnosed with AGE. Incidence of RV-positive AGE decreased from 4.47 per 1,000 children in 2012 to 2.48 per 1,000 in 2018. A total of 4,805 (31%) such children were hospitalized with RV-positive AGE, a decrease from 1.9 per 1,000 children in 2012 to 0,45 per 1,000 in 2018. The length of hospital stays (LOS) of RV-positive AGE was 2.47 ± 1.15 days compared to LOS of RV-negative AGE 1.59 ± 1.17 days (p < .001). The overall cost of RV-positive AGE ($335 ± 200) was higher than that for RV-negative AGE ($280 ± 148) cases (p = .015). Vaccine effectiveness against any case of RV-positive AGE was 75,1% (95% CI: 65–86%). Despite the low level of vaccine coverage, the introduction of RV vaccination had a positive impact on the incidence of RV-positive AGE and related hospitalizations in young children.
No takes yet. Share an insight, caveat, or question.
Gönüllü et al. (2020) conducted an observational in Acute gastroenteritis (n=109,605). Rotavirus vaccination vs. No rotavirus vaccination was evaluated on Any case of rotavirus-positive acute gastroenteritis (VE 75.1%, 95% CI 65-86). Self-financed rotavirus vaccination demonstrated a vaccine effectiveness of 75.1% (95% CI 65-86%) against rotavirus-positive acute gastroenteritis in children ≤60 months of age.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: